Neurotech International Updates Trading Policy to Enhance Compliance

Neurotech International Ltd. ( (AU:NTI) ) has issued an announcement.

Neurotech International Limited has updated its Trading Policy in compliance with ASX Listing Rule 12.10. This revision aims to guide the company’s Key Management Personnel in the sale and purchase of securities, emphasizing the importance of avoiding insider trading. The updated policy reflects the company’s commitment to ethical trading practices and aligns with legal requirements, potentially impacting the company’s governance and stakeholder trust.

More about Neurotech International Ltd.

Neurotech International Limited is a clinical-stage biopharmaceutical development company focusing primarily on pediatric neurological disorders. The company is developing a broad-spectrum oral cannabinoid drug therapy called NTI164 and has conducted multiple clinical trials, including those for Autism Spectrum Disorder, PANDAS/PANS, and Rett Syndrome. Neurotech has also received clearance for a clinical trial in spastic cerebral palsy.

YTD Price Performance: -46.67%

Average Trading Volume: 666,283

Technical Sentiment Signal: Buy

Current Market Cap: A$33.59M

For an in-depth examination of NTI stock, go to TipRanks’ Stock Analysis page.